Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
October 6, 2026

Klygefa / Gefurulimab for Generalised Myasthenia Gravis as of October 2026

MARA Rating Company October 6, 2026

Isembyld / Apitegromab-mstn for Spinal Muscular Atrophy: Evidence Assessment for the United States, EU5, and Japan as of October 2026

MARA Rating Company October 6, 2026

Denecimig / Frehemgo for Prophylaxis of Bleeding Episodes in Haemophilia A as of October 2026

MARA Rating Company October 6, 2026

Farabursen for Autosomal Dominant Polycystic Kidney Disease as of September 2026

MARA Rating Company September 10, 2026

Tozorakimab for COPD as of September 2026

MARA Rating Company September 10, 2026

OTARMENI / Lunsotogene parvec-cwha for biallelic OTOF variant–associated hearing loss as of September 2026

MARA Rating Company September 8, 2026

TRUTAKNA / atacicept-vymj for Primary IgA Nephropathy as of August 2026

MARA Rating Company September 7, 2026

Utebzi / Tebipenem pivoxil for complicated urinary tract infection, including pyelonephritis as of August 2026

MARA Rating Company September 7, 2026

Sintilimab for Non-squamous non-small cell lung cancer (adults) as of August 2026

MARA Rating Company September 7, 2026

Senaparib for First-Line Maintenance of Advanced High-Grade Epithelial Ovarian, Fallopian-Tube, or Primary Peritoneal Cancer as of August 2026

MARA Rating Company September 7, 2026